首页 > 最新文献

Exploratory research in clinical and social pharmacy最新文献

英文 中文
Performance, interpersonal relationships and professional satisfaction: determinants to support pharmaceutical reengineering 绩效、人际关系和职业满意度:支持制药业再造的决定因素
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-22 DOI: 10.1016/j.rcsop.2024.100497
Fernando de Castro Araújo-Neto, Aline Santana Dosea, Divaldo Pereira de Lyra-Jr.

Professionalism represents the ethical contract that binds professionals and society. Its technical aspects, such as the professional practice model, form the foundation for attitudinal and behavioral characteristics, including the fiduciary relationship between pharmacists and patients. Despite significant interest in the topic, contextualizing professionalism proves to be a challenging endeavor, relying on collaboration among formal leaders, academics, and practitioners in the field. Consequently, defining, understanding, teaching, and evaluating pharmaceutical professionalism contribute to shape societal perceptions and the understanding of pharmacists and students, who may occasionally struggle to grasp the underlying rationale behind professional practices. Moreover, contextualizing professionalism entails addressing various challenges, such as fostering support for professionalism and its adaptation, which encompasses pharmacists' performance across diverse clinical services, their interpersonal interactions with patients, families, communities, and fellow healthcare professionals, as well as personal job satisfaction amidst obstacles as job insecurity, ethical dilemmas, and compromised autonomy.

职业精神代表着约束专业人员和社会的道德契约。其技术层面,如专业实践模式,构成了态度和行为特征的基础,包括药剂师与患者之间的信托关系。尽管人们对这一主题兴趣浓厚,但事实证明,将专业精神融入背景是一项具有挑战性的工作,需要该领域的正式领导者、学者和从业人员通力合作。因此,定义、理解、教授和评估医药职业精神有助于形成社会观念,也有助于药剂师和学生的理解,他们有时可能难以掌握职业实践背后的基本原理。此外,将专业精神融入环境需要应对各种挑战,例如促进对专业精神的支持和适应,这包括药剂师在不同临床服务中的表现,他们与患者、家庭、社区和其他医疗保健专业人员的人际互动,以及在工作不稳定、道德困境和自主性受损等障碍中的个人工作满意度。
{"title":"Performance, interpersonal relationships and professional satisfaction: determinants to support pharmaceutical reengineering","authors":"Fernando de Castro Araújo-Neto,&nbsp;Aline Santana Dosea,&nbsp;Divaldo Pereira de Lyra-Jr.","doi":"10.1016/j.rcsop.2024.100497","DOIUrl":"10.1016/j.rcsop.2024.100497","url":null,"abstract":"<div><p>Professionalism represents the ethical contract that binds professionals and society. Its technical aspects, such as the professional practice model, form the foundation for attitudinal and behavioral characteristics, including the fiduciary relationship between pharmacists and patients. Despite significant interest in the topic, contextualizing professionalism proves to be a challenging endeavor, relying on collaboration among formal leaders, academics, and practitioners in the field. Consequently, defining, understanding, teaching, and evaluating pharmaceutical professionalism contribute to shape societal perceptions and the understanding of pharmacists and students, who may occasionally struggle to grasp the underlying rationale behind professional practices. Moreover, contextualizing professionalism entails addressing various challenges, such as fostering support for professionalism and its adaptation, which encompasses pharmacists' performance across diverse clinical services, their interpersonal interactions with patients, families, communities, and fellow healthcare professionals, as well as personal job satisfaction amidst obstacles as job insecurity, ethical dilemmas, and compromised autonomy.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100497"},"PeriodicalIF":1.8,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000945/pdfft?md5=c5f94528c671a2959556b977591848d1&pid=1-s2.0-S2667276624000945-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142058471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonsteroidal anti-inflammatory drug use by patients: Impact of modular educational training on pharmacists' questioning, counselling and risk assessments 患者使用非甾体抗炎药:模块化教育培训对药剂师提问、咨询和风险评估的影响
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-20 DOI: 10.1016/j.rcsop.2024.100494
Segun Johnson Showande, Tolulope Eunice Akinbode

Background

Nonsteroidal anti-inflammatory drugs (NSAIDs)-related morbidity and mortality can be reduced through medication counselling and risk reduction.

Objectives

This study evaluated the impact of short online modular NSAID training on the type and quality of questions asked, risk factors assessed, and counselling offered by community pharmacists to NSAID users.

Methods

A cross-sectional questionnaire-guided survey conducted in Ibadan, Nigeria, among 87 pharmacists evaluated the frequency of counselling, NSAID risk factor assessment and barriers to risk assessment. Additionally, a before-and-after RCT was used to evaluate the impact of short online modular NSAID training for the intervention group (IG) on the type and quality of the questions asked, counselling provided, and risk assessed by the pharmacists. Eight standardised patients, aged 25–43 years, four at pre- and postintervention, presented four standardised scenarios at community pharmacies [IG, n = 22, control group (CG, n = 30)] to assess these outcomes. The quality of each outcome (questions asked, counselling offered and risk assessed) was classified as poor (0–≤20%), fair (>20–≤40%), moderate (>40 – ≤60%), or optimal (>60–100%). The data are presented with descriptive statistics.

Results

The community pharmacists reported counselling patients on NSAID precautions (80–86%) and dosages (51–69%). Gastrointestinal bleeding risk was assessed by 61–89% of the pharmacists, and time constraints (39–42%) and patient impatience (47–75%) were some barriers to risk assessment. Online modular educational intervention significantly improved the types and quality of questions asked by pharmacists (CG: poor to fair, 16%–21%; IG: poor to moderate, 14%–45%), NSAID risk factors assessed (CG: poor to poor, 10%–9%; IG: poor to fair, 11%–27%) and counselling offered (CG: poor to poor, 6%–7%; IG: poor to fair, 6%–22%).

Conclusions

Short online modular educational training on NSAIDs improved the types and quality of the questions asked, NSAID risk factors assessed, and counselling provided by community pharmacists to patients during consultations.

背景非甾体抗炎药(NSAID)相关的发病率和死亡率可以通过用药咨询和降低风险来减少。方法在尼日利亚伊巴丹对 87 名药剂师进行了横断面问卷指导调查,评估了咨询频率、NSAID 风险因素评估和风险评估障碍。此外,还进行了一项前后对比研究,评估为干预组(IG)提供的非甾体抗炎药短期在线模块化培训对药剂师所提问题的类型和质量、提供的咨询以及风险评估的影响。八名年龄在 25-43 岁之间的标准化患者(干预前和干预后各四名)在社区药房[IG,n = 22,对照组(CG,n = 30]]展示了四种标准化情景,以评估这些结果。每个结果(提出的问题、提供的咨询和评估的风险)的质量分为差(0-≤20%)、一般(20-≤40%)、中等(40-≤60%)或最佳(60-100%)。结果社区药剂师向患者提供了有关非甾体抗炎药预防措施(80%-86%)和剂量(51%-69%)的咨询。61-89%的药剂师评估了胃肠道出血风险,而时间限制(39-42%)和患者不耐烦(47-75%)是风险评估的一些障碍。在线模块化教育干预明显改善了药剂师所提问题的类型和质量(CG:差至一般,16%-21%;IG:差至中等,14%-45%)、评估的非甾体抗炎药风险因素(CG:差至较差,10%-9%;IG:差至一般,11%-27%)和提供的咨询服务(CG:差至较差,6%-7%;IG:差至一般,6%-22%)。结论关于非甾体抗炎药的短期在线模块化教育培训提高了社区药剂师在咨询过程中向患者提出的问题类型和质量、评估的非甾体抗炎药风险因素以及提供的咨询服务。
{"title":"Nonsteroidal anti-inflammatory drug use by patients: Impact of modular educational training on pharmacists' questioning, counselling and risk assessments","authors":"Segun Johnson Showande,&nbsp;Tolulope Eunice Akinbode","doi":"10.1016/j.rcsop.2024.100494","DOIUrl":"10.1016/j.rcsop.2024.100494","url":null,"abstract":"<div><h3>Background</h3><p>Nonsteroidal anti-inflammatory drugs (NSAIDs)-related morbidity and mortality can be reduced through medication counselling and risk reduction.</p></div><div><h3>Objectives</h3><p>This study evaluated the impact of short online modular NSAID training on the type and quality of questions asked, risk factors assessed, and counselling offered by community pharmacists to NSAID users.</p></div><div><h3>Methods</h3><p>A cross-sectional questionnaire-guided survey conducted in Ibadan, Nigeria, among 87 pharmacists evaluated the frequency of counselling, NSAID risk factor assessment and barriers to risk assessment. Additionally, a before-and-after RCT was used to evaluate the impact of short online modular NSAID training for the intervention group (IG) on the type and quality of the questions asked, counselling provided, and risk assessed by the pharmacists. Eight standardised patients, aged 25–43 years, four at pre- and postintervention, presented four standardised scenarios at community pharmacies [IG, <em>n</em> = 22, control group (CG, <em>n</em> = 30)] to assess these outcomes. The quality of each outcome (questions asked, counselling offered and risk assessed) was classified as poor (0–≤20%), fair (&gt;20–≤40%), moderate (&gt;40 – ≤60%), or optimal (&gt;60–100%). The data are presented with descriptive statistics.</p></div><div><h3>Results</h3><p>The community pharmacists reported counselling patients on NSAID precautions (80–86%) and dosages (51–69%). Gastrointestinal bleeding risk was assessed by 61–89% of the pharmacists, and time constraints (39–42%) and patient impatience (47–75%) were some barriers to risk assessment. Online modular educational intervention significantly improved the types and quality of questions asked by pharmacists (CG: poor to fair, 16%–21%; IG: poor to moderate, 14%–45%), NSAID risk factors assessed (CG: poor to poor, 10%–9%; IG: poor to fair, 11%–27%) and counselling offered (CG: poor to poor, 6%–7%; IG: poor to fair, 6%–22%).</p></div><div><h3>Conclusions</h3><p>Short online modular educational training on NSAIDs improved the types and quality of the questions asked, NSAID risk factors assessed, and counselling provided by community pharmacists to patients during consultations.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100494"},"PeriodicalIF":1.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266727662400091X/pdfft?md5=3c7c7a6f8be145179d056e50194f5f76&pid=1-s2.0-S266727662400091X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142050243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers and facilitators to implement the redispensing of unused oral anticancer drugs in clinical care: A hybrid-effectiveness type I study 在临床护理中重新分配未使用的口服抗癌药物的障碍和促进因素:混合效益 I 型研究
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-17 DOI: 10.1016/j.rcsop.2024.100493
Elisabeth M. Smale , Eva W. Verkerk , Eibert R. Heerdink , Toine C.G. Egberts , Bart J.F. van den Bemt , Charlotte L. Bekker

Background

Minimizing medication waste through the redispensing of oral anticancer drugs (OADs) that were unused by patients provides economic and environmental benefits, but this is not yet universally implemented in clinical care.

Objective(S)

To identify barriers and facilitators to the implementation of redispensing unused OADs in clinical care.

Methods

A multicentre intervention study following a hybrid effectiveness-implementation type I design was conducted, consisting of semi-structured interviews with key stakeholders involved in the redispensing program: pharmacy employees, prescribing clinicians in oncology and haematology, patients who participated in redispensing and patients who declined trial participation. Questions encompassed experiences and suggestions for future implementation. The Consolidated Framework for Implementation Research (CFIR) guided data collection and categorisation of identified barriers and facilitators through thematic analysis.

Results

In total, 35 interviews were conducted, identifying 15 themes encompassing barriers and facilitators, reflecting all CFIR domains. Facilitators encompassed: 1) convenient process requiring an acceptable time-investment; 2) support from project leaders and implementation champions; 3) being well-motivated by personal values and societal impact; 4) feeling ensured of medication quality upon redispensing; 5) endorsement by healthcare providers for patient participation; 6) clear and personal patient communication; 7) good visibility of intervention successes; and 8) implementation well supported through a collaborative network. Barriers encompassed: 1) unclear target population; 2) redispensing legally prohibited; 3) absence of financial compensation for pharmacies; 4) complexity arising from two parallel work processes; 5) widespread communication on adjustments within local teams challenging; 6) patient's low receptiveness due to burden of oncology treatment; and 7) lack of familiarization among pharmacy technicians.

Conclusions

Facilitators for implementation of redispensing unused drugs mainly related to people's values, motivation, and societal demand, whereas barriers mainly encompassed practical issues, including knowledge, time, financial resources, and legal conditions. Strategies emphasizing the benefits of redispensing and further streamlining process compatibility could support implementation.

背景通过重新发放患者未使用的口服抗癌药(OAD)来减少药物浪费,可带来经济和环境效益,但这一做法尚未在临床护理中得到普遍实施。目的确定在临床护理中重新发放未使用的口服抗癌药的障碍和促进因素。方法 采用混合有效性-实施类型 I 设计进行了一项多中心干预研究,包括对参与重新发放计划的主要利益相关者进行半结构化访谈:药房员工、肿瘤科和血液科开处方的临床医生、参与重新发放的患者以及拒绝参与试验的患者。问题包括经验和对未来实施的建议。结果共进行了 35 次访谈,确定了包含障碍和促进因素的 15 个主题,反映了实施研究综合框架(CFIR)的所有领域。促进因素包括1) 需要投入可接受的时间,过程方便;2) 项目负责人和实施倡导者的支持;3) 个人价值和社会影响的良好激励;4) 重新配药时感觉药品质量有保证;5) 医疗服务提供者对患者参与的认可;6) 清晰和个性化的患者沟通;7) 干预成功的良好可见度;以及 8) 通过协作网络对实施的良好支持。障碍包括1) 目标人群不明确;2) 法律禁止再分配;3) 药房没有经济补偿;4) 两个平行的工作流程造成的复杂性;5) 地方团队内部就调整问题进行广泛沟通具有挑战性;6) 由于肿瘤治疗的负担,患者接受度低;7) 药房技术人员缺乏熟悉情况。结论实施未用药品再分配的促进因素主要与人们的价值观、动机和社会需求有关,而障碍主要包括实际问题,包括知识、时间、经济资源和法律条件。强调重新发放的益处并进一步简化流程的兼容性的策略可以支持重新发放的实施。
{"title":"Barriers and facilitators to implement the redispensing of unused oral anticancer drugs in clinical care: A hybrid-effectiveness type I study","authors":"Elisabeth M. Smale ,&nbsp;Eva W. Verkerk ,&nbsp;Eibert R. Heerdink ,&nbsp;Toine C.G. Egberts ,&nbsp;Bart J.F. van den Bemt ,&nbsp;Charlotte L. Bekker","doi":"10.1016/j.rcsop.2024.100493","DOIUrl":"10.1016/j.rcsop.2024.100493","url":null,"abstract":"<div><h3>Background</h3><p>Minimizing medication waste through the redispensing of oral anticancer drugs (OADs) that were unused by patients provides economic and environmental benefits, but this is not yet universally implemented in clinical care.</p></div><div><h3>Objective(S)</h3><p>To identify barriers and facilitators to the implementation of redispensing unused OADs in clinical care.</p></div><div><h3>Methods</h3><p>A multicentre intervention study following a hybrid effectiveness-implementation type I design was conducted, consisting of semi-structured interviews with key stakeholders involved in the redispensing program: pharmacy employees, prescribing clinicians in oncology and haematology, patients who participated in redispensing and patients who declined trial participation. Questions encompassed experiences and suggestions for future implementation. The Consolidated Framework for Implementation Research (CFIR) guided data collection and categorisation of identified barriers and facilitators through thematic analysis.</p></div><div><h3>Results</h3><p>In total, 35 interviews were conducted, identifying 15 themes encompassing barriers and facilitators, reflecting all CFIR domains. Facilitators encompassed: 1) convenient process requiring an acceptable time-investment; 2) support from project leaders and implementation champions; 3) being well-motivated by personal values and societal impact; 4) feeling ensured of medication quality upon redispensing; 5) endorsement by healthcare providers for patient participation; 6) clear and personal patient communication; 7) good visibility of intervention successes; and 8) implementation well supported through a collaborative network. Barriers encompassed: 1) unclear target population; 2) redispensing legally prohibited; 3) absence of financial compensation for pharmacies; 4) complexity arising from two parallel work processes; 5) widespread communication on adjustments within local teams challenging; 6) patient's low receptiveness due to burden of oncology treatment; and 7) lack of familiarization among pharmacy technicians.</p></div><div><h3>Conclusions</h3><p>Facilitators for implementation of redispensing unused drugs mainly related to people's values, motivation, and societal demand, whereas barriers mainly encompassed practical issues, including knowledge, time, financial resources, and legal conditions. Strategies emphasizing the benefits of redispensing and further streamlining process compatibility could support implementation.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100493"},"PeriodicalIF":1.8,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000908/pdfft?md5=09cc8cad4538f7d46ef03f01abd7fac9&pid=1-s2.0-S2667276624000908-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142050244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the potential of advanced large language models in medication review and reconciliation: A proof-of-concept investigation 发掘先进大型语言模型在药物审查与核对中的潜力:概念验证调查
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-17 DOI: 10.1016/j.rcsop.2024.100492
Kannan Sridharan , Gowri Sivaramakrishnan

Background

Medication review and reconciliation is essential for optimizing drug therapy and minimizing medication errors. Large language models (LLMs) have been recently shown to possess a lot of potential applications in healthcare field due to their abilities of deductive, abductive, and logical reasoning. The present study assessed the abilities of LLMs in medication review and medication reconciliation processes.

Methods

Four LLMs were prompted with appropriate queries related to dosing regimen errors, drug-drug interactions, therapeutic drug monitoring, and genomics-based decision-making process. The veracity of the LLM outputs were verified from validated sources using pre-validated criteria (accuracy, relevancy, risk management, hallucination mitigation, and citations and guidelines). The impacts of the erroneous responses on the patients' safety were categorized either as major or minor.

Results

In the assessment of four LLMs regarding dosing regimen errors, drug-drug interactions, and suggestions for dosing regimen adjustments based on therapeutic drug monitoring and genomics-based individualization of drug therapy, responses were generally consistent across prompts with no clear pattern in response quality among the LLMs. For identification of dosage regimen errors, ChatGPT performed well overall, except for the query related to simvastatin. In terms of potential drug-drug interactions, all LLMs recognized interactions with warfarin but missed the interaction between metoprolol and verapamil. Regarding dosage modifications based on therapeutic drug monitoring, Claude-Instant provided appropriate suggestions for two scenarios and nearly appropriate suggestions for the other two. Similarly, for genomics-based decision-making, Claude-Instant offered satisfactory responses for four scenarios, followed by Gemini for three. Notably, Gemini stood out by providing references to guidelines or citations even without prompting, demonstrating a commitment to accuracy and reliability in its responses. Minor impacts were noted in identifying appropriate dosing regimens and therapeutic drug monitoring, while major impacts were found in identifying drug interactions and making pharmacogenomic-based therapeutic decisions.

Conclusion

Advanced LLMs hold significant promise in revolutionizing the medication review and reconciliation process in healthcare. Diverse impacts on patient safety were observed. Integrating and validating LLMs within electronic health records and prescription systems is essential to harness their full potential and enhance patient safety and care quality.

背景用药审查与协调对于优化药物治疗和减少用药错误至关重要。大语言模型(LLMs)具有演绎、归纳和逻辑推理能力,最近已被证明在医疗保健领域具有很大的应用潜力。本研究评估了大语言模型在用药审核和用药调和过程中的能力。方法:向四个大语言模型提出与用药方案错误、药物相互作用、治疗药物监测和基于基因组学的决策过程有关的适当询问。使用预先验证的标准(准确性、相关性、风险管理、减少幻觉以及引文和指南)对 LLM 输出结果的真实性进行了验证。结果在对四种 LLM 进行的有关配药方案错误、药物间相互作用以及基于治疗药物监测和基于基因组学的个体化药物治疗的配药方案调整建议的评估中,不同提示的回答基本一致,LLM 之间的回答质量没有明显的模式。在识别用药方案错误方面,除了与辛伐他汀相关的查询外,ChatGPT 总体表现良好。在潜在的药物相互作用方面,所有 LLM 都识别出了与华法林的相互作用,但遗漏了美托洛尔和维拉帕米之间的相互作用。关于基于治疗药物监测的剂量调整,Claude-Instant 为两种情况提供了适当的建议,为另外两种情况提供了几乎适当的建议。同样,对于基于基因组学的决策,Claude-Instant 为四种情况提供了令人满意的答复,Gemini 为三种情况提供了令人满意的答复。值得注意的是,Gemini 公司即使在没有提示的情况下也能提供指南或引文参考,显示了其在答复中对准确性和可靠性的承诺。在确定适当的用药方案和治疗药物监测方面,Gemini 的影响较小,而在确定药物相互作用和做出基于药物基因组学的治疗决策方面,Gemini 的影响较大。对患者安全的影响是多方面的。在电子健康记录和处方系统中整合并验证 LLMs 对充分发挥其潜力、提高患者安全和护理质量至关重要。
{"title":"Unlocking the potential of advanced large language models in medication review and reconciliation: A proof-of-concept investigation","authors":"Kannan Sridharan ,&nbsp;Gowri Sivaramakrishnan","doi":"10.1016/j.rcsop.2024.100492","DOIUrl":"10.1016/j.rcsop.2024.100492","url":null,"abstract":"<div><h3>Background</h3><p>Medication review and reconciliation is essential for optimizing drug therapy and minimizing medication errors. Large language models (LLMs) have been recently shown to possess a lot of potential applications in healthcare field due to their abilities of deductive, abductive, and logical reasoning. The present study assessed the abilities of LLMs in medication review and medication reconciliation processes.</p></div><div><h3>Methods</h3><p>Four LLMs were prompted with appropriate queries related to dosing regimen errors, drug-drug interactions, therapeutic drug monitoring, and genomics-based decision-making process. The veracity of the LLM outputs were verified from validated sources using pre-validated criteria (accuracy, relevancy, risk management, hallucination mitigation, and citations and guidelines). The impacts of the erroneous responses on the patients' safety were categorized either as major or minor.</p></div><div><h3>Results</h3><p>In the assessment of four LLMs regarding dosing regimen errors, drug-drug interactions, and suggestions for dosing regimen adjustments based on therapeutic drug monitoring and genomics-based individualization of drug therapy, responses were generally consistent across prompts with no clear pattern in response quality among the LLMs. For identification of dosage regimen errors, ChatGPT performed well overall, except for the query related to simvastatin. In terms of potential drug-drug interactions, all LLMs recognized interactions with warfarin but missed the interaction between metoprolol and verapamil. Regarding dosage modifications based on therapeutic drug monitoring, Claude-Instant provided appropriate suggestions for two scenarios and nearly appropriate suggestions for the other two. Similarly, for genomics-based decision-making, Claude-Instant offered satisfactory responses for four scenarios, followed by Gemini for three. Notably, Gemini stood out by providing references to guidelines or citations even without prompting, demonstrating a commitment to accuracy and reliability in its responses. Minor impacts were noted in identifying appropriate dosing regimens and therapeutic drug monitoring, while major impacts were found in identifying drug interactions and making pharmacogenomic-based therapeutic decisions.</p></div><div><h3>Conclusion</h3><p>Advanced LLMs hold significant promise in revolutionizing the medication review and reconciliation process in healthcare. Diverse impacts on patient safety were observed. Integrating and validating LLMs within electronic health records and prescription systems is essential to harness their full potential and enhance patient safety and care quality.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100492"},"PeriodicalIF":1.8,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000891/pdfft?md5=797afbf458ef3b2f93cf801f382eb184&pid=1-s2.0-S2667276624000891-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142050183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence to assist decision-making on pharmacotherapy: A feasibility study 人工智能辅助药物治疗决策:可行性研究
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-13 DOI: 10.1016/j.rcsop.2024.100491
Michael Bücker , Kreshnik Hoti , Olaf Rose

Background

Artificial intelligence (AI) has the capability to analyze vast amounts of data and has been applied in various healthcare sectors. However, its effectiveness in aiding pharmacotherapy decision-making remains uncertain due to the intricate, patient-specific, and dynamic nature of this field.

Objective

This study sought to investigate the potential of AI in guiding pharmacotherapy decisions using clinical data such as diagnoses, laboratory results, and vital signs obtained from routine patient care.

Methods

Data of a previous study on medication therapy optimization was updated and adapted for the purpose of this study. Analysis was conducted using R software along with the tidymodels extension packages. The dataset was split into 74% for training and 26% for testing. Decision trees were selected as the primary model due to their simplicity, transparency, and interpretability. To prevent overfitting, bootstrapping techniques were employed, and hyperparameters were fine-tuned. Performance metrics such as areas under the curve and accuracies were computed.

Results

The study cohort comprised 101 elderly patients with multiple diagnoses and complex medication regimens. The AI model demonstrated prediction accuracies ranging from 38% to 100% for various cardiovascular drug classes. Laboratory data and vital signs could not be interpreted, as the effect and dependence were unclear for the model. The study revealed that the issue of AI lag time in responding to sudden changes could be addressed by manually adjusting decision trees, a task not feasible with neural networks.

Conclusion

In conclusion, the AI model exhibited promise in recommending appropriate medications for individual patients. While the study identified several obstacles during model development, most were successfully resolved. Future AI studies need to include the drug effect, not only the drug, if laboratory data is part of the decision. This could assist with interpreting their potential relationship. Human oversight and intervention remain essential for an AI-driven pharmacotherapy decision support system to ensure safe and effective patient care.

背景人工智能(AI)具有分析海量数据的能力,已被应用于各种医疗保健领域。然而,由于该领域错综复杂、针对特定患者且动态变化,人工智能在辅助药物治疗决策方面的有效性仍不确定。分析使用 R 软件和 tidymodels 扩展包进行。数据集被分成 74% 用于训练,26% 用于测试。决策树因其简单、透明和可解释性而被选为主要模型。为防止过度拟合,采用了引导技术,并对超参数进行了微调。研究队列由 101 名老年患者组成,他们有多种诊断和复杂的用药方案。人工智能模型对各类心血管药物的预测准确率从 38% 到 100% 不等。实验室数据和生命体征无法解释,因为模型的效果和依赖性不明确。研究表明,人工智能对突变做出反应的滞后时间问题可以通过手动调整决策树来解决,而这是神经网络无法完成的任务。虽然这项研究在模型开发过程中发现了一些障碍,但大部分都得到了成功解决。如果实验室数据是决定的一部分,那么未来的人工智能研究需要包括药物效果,而不仅仅是药物。这有助于解释它们之间的潜在关系。人工智能驱动的药物治疗决策支持系统仍然离不开人工的监督和干预,以确保为患者提供安全有效的治疗。
{"title":"Artificial intelligence to assist decision-making on pharmacotherapy: A feasibility study","authors":"Michael Bücker ,&nbsp;Kreshnik Hoti ,&nbsp;Olaf Rose","doi":"10.1016/j.rcsop.2024.100491","DOIUrl":"10.1016/j.rcsop.2024.100491","url":null,"abstract":"<div><h3>Background</h3><p>Artificial intelligence (AI) has the capability to analyze vast amounts of data and has been applied in various healthcare sectors. However, its effectiveness in aiding pharmacotherapy decision-making remains uncertain due to the intricate, patient-specific, and dynamic nature of this field.</p></div><div><h3>Objective</h3><p>This study sought to investigate the potential of AI in guiding pharmacotherapy decisions using clinical data such as diagnoses, laboratory results, and vital signs obtained from routine patient care.</p></div><div><h3>Methods</h3><p>Data of a previous study on medication therapy optimization was updated and adapted for the purpose of this study. Analysis was conducted using R software along with the tidymodels extension packages. The dataset was split into 74% for training and 26% for testing. Decision trees were selected as the primary model due to their simplicity, transparency, and interpretability. To prevent overfitting, bootstrapping techniques were employed, and hyperparameters were fine-tuned. Performance metrics such as areas under the curve and accuracies were computed.</p></div><div><h3>Results</h3><p>The study cohort comprised 101 elderly patients with multiple diagnoses and complex medication regimens. The AI model demonstrated prediction accuracies ranging from 38% to 100% for various cardiovascular drug classes. Laboratory data and vital signs could not be interpreted, as the effect and dependence were unclear for the model. The study revealed that the issue of AI lag time in responding to sudden changes could be addressed by manually adjusting decision trees, a task not feasible with neural networks.</p></div><div><h3>Conclusion</h3><p>In conclusion, the AI model exhibited promise in recommending appropriate medications for individual patients. While the study identified several obstacles during model development, most were successfully resolved. Future AI studies need to include the drug effect, not only the drug, if laboratory data is part of the decision. This could assist with interpreting their potential relationship. Human oversight and intervention remain essential for an AI-driven pharmacotherapy decision support system to ensure safe and effective patient care.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100491"},"PeriodicalIF":1.8,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266727662400088X/pdfft?md5=b7a2de3513ea1a00e9908eb6b88f7622&pid=1-s2.0-S266727662400088X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141993351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medication management issues perceived by pharmacists and disability caregivers while supporting people with disability 药剂师和残疾人护理人员在为残疾人提供支持时所遇到的药物管理问题
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-13 DOI: 10.1016/j.rcsop.2024.100489
Chelsea Felkai , David Newby , Joyce Cooper , Suzanne Nielsen , Angela Reeves , Hayley Croft

Background

Australia has a notable gap in guidance for pharmacists, caregivers and disability service providers in: (i) supporting people with disabilities (PWD) within the medication management cycle, (ii) understanding their obligations for providing high quality care, and (iii) preventing medication-related harm.

Objective

The objective of this study was to identify medication management issues for PWD from the perspective of disability caregivers and pharmacists when supporting PWD with their medication.

Methods

A qualitative study design using semi-structured interviews of pharmacists and disability caregivers was undertaken across six different states or territories in Australia.

Results

Interviews were conducted with registered pharmacist participants (n=10), and disability workers (n=10). Seven themes emerged for both pharmacists and caregivers, with most sub-themes and codes concordant between the two cohorts. Clinical issues, particularly related to polypharmacy and psychotropic use; confidence in providing medicines and medication information accurately to PWD; practical and behavioural issues caregivers experienced when administering medication; challenges in providing individualised and person-centred care to PWD; inadequate communication and transfer of information between healthcare professionals, caregivers, and PWD; insufficient disability awareness training for pharmacists and medication training for caregivers; and challenges working with provider organisations within the current practice environment were described.

Conclusions

This study highlighted seven areas where issues were perceived to arise in medication management for PWD. By understanding the issues perceived by those directly providing care, it may be possible to improve medication management. Further research is needed to understand the perceived role of pharmacists in supporting medication management for PWD and their caregivers, and how enabling pharmacists scope might reduce medication-related risks and support QUM in this sector.

背景澳大利亚在为药剂师、护理人员和残疾人服务提供者提供以下方面的指导方面存在明显不足:(i) 在药物管理周期内为残疾人(PWD)提供支持;(ii) 了解他们在提供高质量护理方面的义务;(iii) 预防与药物相关的伤害。本研究旨在从残疾人护理人员和药剂师的角度出发,找出在为残疾人提供用药支持时存在的残疾人用药管理问题。方法在澳大利亚六个不同的州或地区对药剂师和残疾人护理人员进行了半结构化访谈,采用定性研究设计。药剂师和护理人员都出现了七个主题,两个群体之间的大多数子主题和代码都是一致的。研究描述了临床问题,特别是与多种药物和精神药物使用相关的问题;为残疾人准确提供药物和用药信息的信心问题;护理人员在用药时遇到的实际和行为问题;为残疾人提供个性化和以人为本的护理时遇到的挑战;医疗保健专业人员、护理人员和残疾人之间的沟通和信息传递不足;药剂师的残疾意识培训和护理人员的用药培训不足;以及在当前实践环境下与医疗机构合作时遇到的挑战。结论本研究强调了残疾人用药管理中出现问题的七个方面。通过了解直接提供护理的人员认为存在的问题,也许可以改善用药管理。我们还需要进一步研究,以了解药剂师在支持残疾人及其护理人员用药管理方面所扮演的角色,以及药剂师的作用范围可如何降低用药相关风险并支持该领域的质量管理。
{"title":"Medication management issues perceived by pharmacists and disability caregivers while supporting people with disability","authors":"Chelsea Felkai ,&nbsp;David Newby ,&nbsp;Joyce Cooper ,&nbsp;Suzanne Nielsen ,&nbsp;Angela Reeves ,&nbsp;Hayley Croft","doi":"10.1016/j.rcsop.2024.100489","DOIUrl":"10.1016/j.rcsop.2024.100489","url":null,"abstract":"<div><h3>Background</h3><p>Australia has a notable gap in guidance for pharmacists, caregivers and disability service providers in: (i) supporting people with disabilities (PWD) within the medication management cycle, (ii) understanding their obligations for providing high quality care, and (iii) preventing medication-related harm.</p></div><div><h3>Objective</h3><p>The objective of this study was to identify medication management issues for PWD from the perspective of disability caregivers and pharmacists when supporting PWD with their medication.</p></div><div><h3>Methods</h3><p>A qualitative study design using semi-structured interviews of pharmacists and disability caregivers was undertaken across six different states or territories in Australia.</p></div><div><h3>Results</h3><p>Interviews were conducted with registered pharmacist participants (n=10), and disability workers (n=10). Seven themes emerged for both pharmacists and caregivers, with most sub-themes and codes concordant between the two cohorts. Clinical issues, particularly related to polypharmacy and psychotropic use; confidence in providing medicines and medication information accurately to PWD; practical and behavioural issues caregivers experienced when administering medication; challenges in providing individualised and person-centred care to PWD; inadequate communication and transfer of information between healthcare professionals, caregivers, and PWD; insufficient disability awareness training for pharmacists and medication training for caregivers; and challenges working with provider organisations within the current practice environment were described.</p></div><div><h3>Conclusions</h3><p>This study highlighted seven areas where issues were perceived to arise in medication management for PWD. By understanding the issues perceived by those directly providing care, it may be possible to improve medication management. Further research is needed to understand the perceived role of pharmacists in supporting medication management for PWD and their caregivers, and how enabling pharmacists scope might reduce medication-related risks and support QUM in this sector.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100489"},"PeriodicalIF":1.8,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000866/pdfft?md5=2695058af01bafef7a13be91e1adaecb&pid=1-s2.0-S2667276624000866-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142050184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing South Dakota Pharmacist Perspectives of Pharmacy Services in Rural versus Urban settings 比较南达科他州药剂师对农村和城市药房服务的看法
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-08 DOI: 10.1016/j.rcsop.2024.100490
Erin E. Miller , Aaron Hunt , Alex Middendorf , Deidra Van Gilder , Abigayle Blanchette , Abigail Sirek , Sharrel Pinto

Background

Access to healthcare services is a major barrier to residents of the rural state of South Dakota. As a highly accessible member of the healthcare team, outpatient pharmacists can play a key role in a patient's healthcare journey. There is a need to identify the unique barriers and facilitators pharmacists in both rural and urban areas face to maximize the impact of their role.

Objective

The objective of this work was to compare perceptions of rural and urban pharmacists regarding the facilitators and barriers to providing patient care in South Dakota.

Methods

This qualitative project highlights results from interviews and focus group sessions with a convenience sample of South Dakota pharmacists. Participants were recruited using a referral word-of-mouth system, contracts with healthcare market research agencies, newspaper advertisements, and posters displayed in public locations in South Dakota. Practice location was characterized as rural or urban based on United States Department of Agriculture definitions. Findings from interviews and focus group sessions were coded and analyzed using content analysis by two student researchers.

Results

Participants included 12 rural-practicing and 21 urban-practicing pharmacists in South Dakota. In both rural and urban areas, key barriers included communication with providers (50% rural; 50% urban), lack of electronic health record access (25% rural; 14% urban), not enough staff (22% rural; 20% urban), and patient misunderstanding the scope of pharmacy (22% rural; 40% urban). Barriers specific to rural areas included time to provide services (22%), having smaller facilities (27%) and provider hesitation regarding collaborative practice agreements (29%). There were no urban-specific barriers. Facilitators specific to urban areas included frequent communication with patients (6.1%) and good quality support staff (9.1%). There were no rural-specific facilitators.

Conclusions

Next steps include increasing awareness of pharmacy-based patient care services, researching further to identify the extent to which facilitators and barriers influence the ability to initiate and sustain pharmacy services in rural and urban areas, and providing support to pharmacies to overcome barriers and leverage facilitators.

背景对于南达科他州的农村居民来说,获得医疗保健服务是一个主要障碍。门诊药剂师作为医疗团队中极易接触到的一员,可以在患者的医疗过程中发挥关键作用。这项工作的目的是比较农村和城市药剂师对在南达科他州为患者提供医疗保健服务的促进因素和障碍的看法。方法该定性项目突出强调了对南达科他州药剂师进行方便抽样的访谈和焦点小组会议的结果。我们通过口碑转介系统、与医疗保健市场调研机构签订合同、报纸广告以及在南达科他州公共场所张贴海报等方式招募参与者。根据美国农业部的定义,实践地点被划分为农村或城市。两名学生研究员通过内容分析法对访谈和焦点小组会议的结果进行了编码和分析。在农村和城市地区,主要障碍包括与医疗服务提供者的沟通(50% 的农村地区;50% 的城市地区)、缺乏电子健康记录访问(25% 的农村地区;14% 的城市地区)、人手不足(22% 的农村地区;20% 的城市地区)以及患者对药学范围的误解(22% 的农村地区;40% 的城市地区)。农村地区特有的障碍包括提供服务的时间(22%)、设施规模较小(27%)以及提供者对合作实践协议犹豫不决(29%)。没有城市特有的障碍。城市地区特有的促进因素包括与患者的频繁沟通(6.1%)和高素质的辅助人员(9.1%)。结论接下来的步骤包括:提高对基于药房的患者护理服务的认识;进一步研究以确定促进因素和障碍在多大程度上影响了在农村和城市地区启动和维持药房服务的能力;以及为药房提供支持以克服障碍和利用促进因素。
{"title":"Comparing South Dakota Pharmacist Perspectives of Pharmacy Services in Rural versus Urban settings","authors":"Erin E. Miller ,&nbsp;Aaron Hunt ,&nbsp;Alex Middendorf ,&nbsp;Deidra Van Gilder ,&nbsp;Abigayle Blanchette ,&nbsp;Abigail Sirek ,&nbsp;Sharrel Pinto","doi":"10.1016/j.rcsop.2024.100490","DOIUrl":"10.1016/j.rcsop.2024.100490","url":null,"abstract":"<div><h3>Background</h3><p>Access to healthcare services is a major barrier to residents of the rural state of South Dakota. As a highly accessible member of the healthcare team, outpatient pharmacists can play a key role in a patient's healthcare journey. There is a need to identify the unique barriers and facilitators pharmacists in both rural and urban areas face to maximize the impact of their role.</p></div><div><h3>Objective</h3><p>The objective of this work was to compare perceptions of rural and urban pharmacists regarding the facilitators and barriers to providing patient care in South Dakota.</p></div><div><h3>Methods</h3><p>This qualitative project highlights results from interviews and focus group sessions with a convenience sample of South Dakota pharmacists. Participants were recruited using a referral word-of-mouth system, contracts with healthcare market research agencies, newspaper advertisements, and posters displayed in public locations in South Dakota. Practice location was characterized as rural or urban based on United States Department of Agriculture definitions. Findings from interviews and focus group sessions were coded and analyzed using content analysis by two student researchers.</p></div><div><h3>Results</h3><p>Participants included 12 rural-practicing and 21 urban-practicing pharmacists in South Dakota. In both rural and urban areas, key barriers included communication with providers (50% rural; 50% urban), lack of electronic health record access (25% rural; 14% urban), not enough staff (22% rural; 20% urban), and patient misunderstanding the scope of pharmacy (22% rural; 40% urban). Barriers specific to rural areas included time to provide services (22%), having smaller facilities (27%) and provider hesitation regarding collaborative practice agreements (29%). There were no urban-specific barriers. Facilitators specific to urban areas included frequent communication with patients (6.1%) and good quality support staff (9.1%). There were no rural-specific facilitators.</p></div><div><h3>Conclusions</h3><p>Next steps include increasing awareness of pharmacy-based patient care services, researching further to identify the extent to which facilitators and barriers influence the ability to initiate and sustain pharmacy services in rural and urban areas, and providing support to pharmacies to overcome barriers and leverage facilitators.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100490"},"PeriodicalIF":1.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000878/pdfft?md5=f2a28af8a8f8fc3c1610e0bc7a336b88&pid=1-s2.0-S2667276624000878-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142044879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research on PIVAS risk assessment and control strategy based on quality risk management (QRM) 基于质量风险管理(QRM)的 PIVAS 风险评估和控制策略研究
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-08 DOI: 10.1016/j.rcsop.2024.100487
Qining Qiu , Guohong Zhu , Gang Peng , Zhenhui Chen , Zhenmao Zhu , Yan Zhou , Yanrong Ye , Yun Shen , Lumin Wang

Objective: This study aims to evaluate the effectiveness of the Quality Risk Management (QRM) system in hospital pharmacy intravenous admixture services (PIVAS). Methods: Failure Modes and Effects Analysis (FMEA) and risk matrix methods were used to systematically assess the critical risk points in PIVAS. By collecting and comparing relevant data from 2019 to 2023, key performance indicators (KPIs) before and after the implementation of the QRM system were quantitatively evaluated. Results: The results showed that the safety and efficiency of pharmacy services significantly improved after the implementation of the QRM system. The medication error rate significantly decreased from 3.2% to 1.1%, the average medication preparation time reduced from 15.5 min to 8.2 min, and staff satisfaction increased from 6.0 to 8.5 points. Other indicators, such as cross-contamination rates and handling errors, also showed significant improvement (all outcomes p < 0.001). Discussion: Systematic risk management effectively enhanced the operational performance of PIVAS, reduced medication errors, and improved the quality of healthcare services. This study highlights the key role of QRM in enhancing medication safety and productivity, providing empirical support for the implementation of similar systems in other healthcare institutions.

研究目的本研究旨在评估质量风险管理(QRM)系统在医院药房静脉注射服务(PIVAS)中的有效性。方法:采用故障模式及影响分析法(FMEA)和质量风险管理方法(QRM):采用故障模式与影响分析法(FMEA)和风险矩阵法对 PIVAS 的关键风险点进行系统评估。通过收集和比较 2019 年至 2023 年的相关数据,对实施 QRM 系统前后的关键绩效指标(KPIs)进行量化评估。结果显示结果显示,实施 QRM 系统后,药房服务的安全性和效率明显提高。用药错误率从 3.2% 明显降低到 1.1%,平均配药时间从 15.5 分钟缩短到 8.2 分钟,员工满意度从 6.0 分提高到 8.5 分。交叉感染率和操作失误等其他指标也有显著改善(所有结果 p < 0.001)。讨论系统化风险管理有效提高了 PIVAS 的运行绩效,减少了用药错误,提高了医疗服务质量。这项研究强调了 QRM 在提高用药安全和生产率方面的关键作用,为其他医疗机构实施类似系统提供了经验支持。
{"title":"Research on PIVAS risk assessment and control strategy based on quality risk management (QRM)","authors":"Qining Qiu ,&nbsp;Guohong Zhu ,&nbsp;Gang Peng ,&nbsp;Zhenhui Chen ,&nbsp;Zhenmao Zhu ,&nbsp;Yan Zhou ,&nbsp;Yanrong Ye ,&nbsp;Yun Shen ,&nbsp;Lumin Wang","doi":"10.1016/j.rcsop.2024.100487","DOIUrl":"10.1016/j.rcsop.2024.100487","url":null,"abstract":"<div><p>Objective: This study aims to evaluate the effectiveness of the Quality Risk Management (QRM) system in hospital pharmacy intravenous admixture services (PIVAS). Methods: Failure Modes and Effects Analysis (FMEA) and risk matrix methods were used to systematically assess the critical risk points in PIVAS. By collecting and comparing relevant data from 2019 to 2023, key performance indicators (KPIs) before and after the implementation of the QRM system were quantitatively evaluated. Results: The results showed that the safety and efficiency of pharmacy services significantly improved after the implementation of the QRM system. The medication error rate significantly decreased from 3.2% to 1.1%, the average medication preparation time reduced from 15.5 min to 8.2 min, and staff satisfaction increased from 6.0 to 8.5 points. Other indicators, such as cross-contamination rates and handling errors, also showed significant improvement (all outcomes <em>p</em> &lt; 0.001). Discussion: Systematic risk management effectively enhanced the operational performance of PIVAS, reduced medication errors, and improved the quality of healthcare services. This study highlights the key role of QRM in enhancing medication safety and productivity, providing empirical support for the implementation of similar systems in other healthcare institutions.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100487"},"PeriodicalIF":1.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000842/pdfft?md5=5dd2aa57b500ce160de5b42211b8ea3d&pid=1-s2.0-S2667276624000842-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141964466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Linking Inner Context and Innovation Factors: Examining a pharmacy-based intervention through the eyes of pharmacy staff 将内在环境和创新因素联系起来:通过药房员工的视角审视基于药房的干预措施
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-05 DOI: 10.1016/j.rcsop.2024.100486
Taylor L. Watterson , Jukrin Moon , Jamie A. Stone , Aaron M. Gilson , Maria E. Berbakov , Emily L. Hoffins , Jason S. Chladek , Elin C. Lehnbom , Stephanie M. Resendiz , Shiying Mai , Kenneth D. Walker , Joel D. Gollhardt , Michelle A. Chui

Introduction: Community pharmacies, as unique and accessible healthcare venues, are ideal locations to implement interventions aiming to improve patient care. However, these interventions may increase workload or disrupt workflow for community pharmacists, technicians, and other staff members, threatening long-term sustainment. There are growing calls from the field of implementation science to design for intervention sustainment and maintenance by maximizing innovation fit. Senior Safe™, an intervention to facilitate safer over-the-counter (OTC) product selection by older adults, serves as a case study to examine the congruence between Innovation Factors and community pharmacy Inner Context constructs and their implications for workload and sustainment.

Methods: Using the Exploration, Preparation, Implementation, Sustainment (EPIS) framework, this qualitative study identified factors surrounding Senior Safe implementation. Semi-structured interviews were conducted with staff from pharmacies where Senior Safe was implemented. Two coders independently analyzed interview transcripts using deductive analysis based on EPIS constructs. Thematic analysis was used to generate three themes that encapsulated innovation fit.

Results: Nineteen pharmacy staff members participated, with the majority reporting no significant change in their workload or workflow due to Senior Safe. Interview feedback supported a pre-existing culture of the healthcare system to engage patients, of leadership commitment to patient safety initiatives, and of an amplified role of pharmacy technicians.

Discussion and Conclusion: Pharmacy staff interviews revealed congruence between Innovation Factors and Inner Context that likely yielded intervention workload neutrality. This study highlighted the importance for researchers to consider maintenance and sustainability when designing and implementing an intervention and the critical influence of culture and leadership support during this process.

导言:社区药房作为独特而方便的医疗保健场所,是实施旨在改善患者护理的干预措施的理想场所。然而,这些干预措施可能会增加社区药剂师、技术人员和其他工作人员的工作量或扰乱工作流程,从而威胁到干预措施的长期可持续性。实施科学领域越来越多地呼吁通过最大化创新契合度来设计干预措施的持续性和维护性。Senior Safe™ 是一项旨在促进老年人更安全地选择非处方药(OTC)产品的干预措施,该项目作为一项案例研究,考察了创新因素与社区药房内在环境构建之间的一致性及其对工作量和持续性的影响:本定性研究采用探索、准备、实施、持续(EPIS)框架,确定了围绕 Senior Safe 实施的各种因素。对实施 Senior Safe 的药房员工进行了半结构化访谈。两名编码员根据 EPIS 构建采用演绎分析法对访谈记录进行了独立分析。通过主题分析,得出了三个概括创新契合度的主题:结果:19 名药房工作人员参与了访谈,其中大多数人表示他们的工作量或工作流程没有因为 Senior Safe 的实施而发生重大变化。访谈反馈支持医疗保健系统预先存在的让患者参与的文化、领导层对患者安全倡议的承诺以及药剂师作用的扩大:对药剂师的访谈显示,创新因素与内在环境之间的一致性很可能导致干预工作量的中立性。本研究强调了研究人员在设计和实施干预措施时考虑维护和可持续性的重要性,以及在此过程中文化和领导支持的关键影响。
{"title":"Linking Inner Context and Innovation Factors: Examining a pharmacy-based intervention through the eyes of pharmacy staff","authors":"Taylor L. Watterson ,&nbsp;Jukrin Moon ,&nbsp;Jamie A. Stone ,&nbsp;Aaron M. Gilson ,&nbsp;Maria E. Berbakov ,&nbsp;Emily L. Hoffins ,&nbsp;Jason S. Chladek ,&nbsp;Elin C. Lehnbom ,&nbsp;Stephanie M. Resendiz ,&nbsp;Shiying Mai ,&nbsp;Kenneth D. Walker ,&nbsp;Joel D. Gollhardt ,&nbsp;Michelle A. Chui","doi":"10.1016/j.rcsop.2024.100486","DOIUrl":"10.1016/j.rcsop.2024.100486","url":null,"abstract":"<div><p>Introduction: Community pharmacies, as unique and accessible healthcare venues, are ideal locations to implement interventions aiming to improve patient care. However, these interventions may increase workload or disrupt workflow for community pharmacists, technicians, and other staff members, threatening long-term sustainment. There are growing calls from the field of implementation science to design for intervention sustainment and maintenance by maximizing innovation fit. Senior Safe™, an intervention to facilitate safer over-the-counter (OTC) product selection by older adults, serves as a case study to examine the congruence between Innovation Factors and community pharmacy Inner Context constructs and their implications for workload and sustainment.</p><p>Methods: Using the Exploration, Preparation, Implementation, Sustainment (EPIS) framework, this qualitative study identified factors surrounding Senior Safe implementation. Semi-structured interviews were conducted with staff from pharmacies where Senior Safe was implemented. Two coders independently analyzed interview transcripts using deductive analysis based on EPIS constructs. Thematic analysis was used to generate three themes that encapsulated innovation fit.</p><p>Results: Nineteen pharmacy staff members participated, with the majority reporting no significant change in their workload or workflow due to Senior Safe. Interview feedback supported a pre-existing culture of the healthcare system to engage patients, of leadership commitment to patient safety initiatives, and of an amplified role of pharmacy technicians.</p><p>Discussion and Conclusion: Pharmacy staff interviews revealed congruence between Innovation Factors and Inner Context that likely yielded intervention workload neutrality. This study highlighted the importance for researchers to consider maintenance and sustainability when designing and implementing an intervention and the critical influence of culture and leadership support during this process.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100486"},"PeriodicalIF":1.8,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000830/pdfft?md5=ff487a49cb1c8c207c8dc0f6c886066f&pid=1-s2.0-S2667276624000830-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141963865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Key modifiable risk factors for self-medication among university students: An observational study 大学生自我药疗的主要可调整风险因素:观察研究
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-29 DOI: 10.1016/j.rcsop.2024.100483
Ebtihag O. Alenzi , Shahad Khalid A. Bedaiwi , Rahma Hamayun , Abdulaziz Salamah T. Alanazi , Manal S. Fawzy

Background

Self-medication among university students is becoming a health concern, especially during examinations and stress. This pattern of medication use among students could lead to adverse health consequences if it is not addressed and tackled. Thus, this study investigated the most associated factors with this practice among students.

Methods

An observational cross-sectional study was conducted among university students in Northern Borders Province, Saudi Arabia. A total of 220 students were selected and took part in the survey. Data was collected through a self-administered questionnaire. The survey was distributed among participants to answer five sections: demographic and socioeconomic characteristics, health status problems, satisfaction with academic performance, and self-medication questions. The content validity was tested using a pilot sample of 30 students. The descriptive, univariate, and multivariate analyses were conducted using the Statistical Package for Social Science program.

Results

In the present sample of university students, the response rate was 100%. Approximately one-third reported using medications without prescriptions, and 83% of them have used medications three times at most during the past 12 months. Headache was the most common reason for use (59%), followed by fever (20%). Adjusted multivariate analysis showed that students who were 21–24 years of age (OR = 3.79, 95% CI = 1.21–11.82), female (OR = 2.43, 95% CI = 1.03–5.72), and living alone in private housing (OR = 3.62, 95% CI = 1.32–9.90) were at high risk of self-medication as compared to their counterparts. However, students in the last years of college (fourth (OR = 0.14, 95% CI = 0.03–0.62), fifth (OR = 0.21, 95% CI = 0.05–0.95), sixth (OR = 0.05, 95% CI = 0.01–0.35)) were at lower risk as compared to their counterparts.

Conclusion

The study found that self-medication was common among university students, with higher rates among those who were 21–24 years old, female, and living alone in private housing, but lower rates among students in the later years of college. Educational programs and awareness campaigns should target students who are at higher risk of practicing self-medication to avoid misuse of over-the-counter medications.

背景大学生自我用药正成为一个健康问题,尤其是在考试和压力大的时候。如果不加以重视和解决,学生中的这种用药模式可能会导致不良的健康后果。因此,本研究调查了与学生自我用药行为最相关的因素。共选取了 220 名学生参与调查。数据通过自制问卷收集。调查问卷分发给参与者,要求他们回答五个部分的问题:人口和社会经济特征、健康状况问题、学习成绩满意度和自我治疗问题。通过对 30 名学生进行试点抽样,检验了问卷内容的有效性。使用社会科学统计软件包程序进行了描述性分析、单变量分析和多变量分析。约有三分之一的人表示在没有处方的情况下使用过药物,其中 83% 的人在过去 12 个月中最多使用过三次药物。头痛是最常见的用药原因(59%),其次是发烧(20%)。调整后的多变量分析显示,与同龄人相比,21-24 岁(OR = 3.79,95% CI = 1.21-11.82)、女性(OR = 2.43,95% CI = 1.03-5.72)和独自居住在私人住宅中(OR = 3.62,95% CI = 1.32-9.90)的学生自我用药的风险较高。结论 该研究发现,自我药疗在大学生中很常见,21-24 岁、女性、独自居住在私人住宅中的学生自我药疗的比例较高,但大学后期的学生自我药疗的比例较低。应针对自我药疗风险较高的学生开展教育计划和宣传活动,以避免滥用非处方药。
{"title":"Key modifiable risk factors for self-medication among university students: An observational study","authors":"Ebtihag O. Alenzi ,&nbsp;Shahad Khalid A. Bedaiwi ,&nbsp;Rahma Hamayun ,&nbsp;Abdulaziz Salamah T. Alanazi ,&nbsp;Manal S. Fawzy","doi":"10.1016/j.rcsop.2024.100483","DOIUrl":"10.1016/j.rcsop.2024.100483","url":null,"abstract":"<div><h3>Background</h3><p>Self-medication among university students is becoming a health concern, especially during examinations and stress. This pattern of medication use among students could lead to adverse health consequences if it is not addressed and tackled. Thus, this study investigated the most associated factors with this practice among students.</p></div><div><h3>Methods</h3><p>An observational cross-sectional study was conducted among university students in Northern Borders Province, Saudi Arabia. A total of 220 students were selected and took part in the survey. Data was collected through a self-administered questionnaire. The survey was distributed among participants to answer five sections: demographic and socioeconomic characteristics, health status problems, satisfaction with academic performance, and self-medication questions. The content validity was tested using a pilot sample of 30 students. The descriptive, univariate, and multivariate analyses were conducted using the Statistical Package for Social Science program.</p></div><div><h3>Results</h3><p>In the present sample of university students, the response rate was 100%. Approximately one-third reported using medications without prescriptions, and 83% of them have used medications three times at most during the past 12 months. Headache was the most common reason for use (59%), followed by fever (20%). Adjusted multivariate analysis showed that students who were 21–24 years of age (OR = 3.79, 95% CI = 1.21–11.82), female (OR = 2.43, 95% CI = 1.03–5.72), and living alone in private housing (OR = 3.62, 95% CI = 1.32–9.90) were at high risk of self-medication as compared to their counterparts. However, students in the last years of college (fourth (OR = 0.14, 95% CI = 0.03–0.62), fifth (OR = 0.21, 95% CI = 0.05–0.95), sixth (OR = 0.05, 95% CI = 0.01–0.35)) were at lower risk as compared to their counterparts.</p></div><div><h3>Conclusion</h3><p>The study found that self-medication was common among university students, with higher rates among those who were 21–24 years old, female, and living alone in private housing, but lower rates among students in the later years of college. Educational programs and awareness campaigns should target students who are at higher risk of practicing self-medication to avoid misuse of over-the-counter medications.</p></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"15 ","pages":"Article 100483"},"PeriodicalIF":1.8,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667276624000805/pdfft?md5=54808706b978a662f683269ddb011957&pid=1-s2.0-S2667276624000805-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Exploratory research in clinical and social pharmacy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1